Previous Close | 0.0000 |
Open | 0.0910 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0900 - 0.0910 |
52 Week Range | 0.0900 - 150.0000 |
Volume | |
Avg. Volume | 0 |
Market Cap | 6,396 |
Beta (5Y Monthly) | 0.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2,471.1899 |
Earnings Date | May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023. Anders Fink Vadsholt states:” With the latest progress in our US security class act
Company announcement Orphazyme A/SNo. 8/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2022 Took note of the Board of Directors’ report on the Company’s activities in the past financial year;Adopted the Company’s annual report for 2022Adopted that the profit related to the financial
Company announcement Orphazyme A/SNo. 07/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected a